SUPN SUPERNUS PHARMACEUTICALS, INC.
P/E
--
Forward P/E
20.16
Price/Sales
3.063
Beta
0.56
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Supernus Awarded 7-Year Orphan-Drug Exclusivity for Parkinson's Drug ONAPGO
Supernus Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has recognized a seven-year period of orphan-drug market exclusivity for...
Supernus Pharmaceuticals to report third quarter 2026 financial results on October 29
Supernus Pharmaceuticals announced it will release its third quarter 2026 financial and business results after the market closes on Thursday, October 29, 2026....
Supernus Shareholders Approve Merger with Indivior Pharmaceuticals
Supernus Pharmaceuticals, Inc. (SUPN) announced that its stockholders have voted to approve the previously disclosed merger agreement with Indivior...
Steve Cohen's Point72 Exits $68M Position in Supernus Pharmaceuticals
In a significant portfolio move, Steve Cohen's Point72 Asset Management completely exited its stake in Supernus Pharmaceuticals (SUPN), selling all 1.32...